JP2015504897A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504897A5
JP2015504897A5 JP2014552287A JP2014552287A JP2015504897A5 JP 2015504897 A5 JP2015504897 A5 JP 2015504897A5 JP 2014552287 A JP2014552287 A JP 2014552287A JP 2014552287 A JP2014552287 A JP 2014552287A JP 2015504897 A5 JP2015504897 A5 JP 2015504897A5
Authority
JP
Japan
Prior art keywords
virus
hpv
protein
antigen
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552287A
Other languages
English (en)
Japanese (ja)
Other versions
JP6185932B2 (ja
JP2015504897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/020960 external-priority patent/WO2013106525A1/en
Publication of JP2015504897A publication Critical patent/JP2015504897A/ja
Publication of JP2015504897A5 publication Critical patent/JP2015504897A5/ja
Application granted granted Critical
Publication of JP6185932B2 publication Critical patent/JP6185932B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552287A 2012-01-12 2013-01-10 免疫原性のhpvのl2を含むvlp並びに関連する組成物及び方法 Expired - Fee Related JP6185932B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261585839P 2012-01-12 2012-01-12
US61/585,839 2012-01-12
PCT/US2013/020960 WO2013106525A1 (en) 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods

Publications (3)

Publication Number Publication Date
JP2015504897A JP2015504897A (ja) 2015-02-16
JP2015504897A5 true JP2015504897A5 (enExample) 2016-03-03
JP6185932B2 JP6185932B2 (ja) 2017-08-23

Family

ID=48781889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552287A Expired - Fee Related JP6185932B2 (ja) 2012-01-12 2013-01-10 免疫原性のhpvのl2を含むvlp並びに関連する組成物及び方法

Country Status (8)

Country Link
EP (1) EP2802349B1 (enExample)
JP (1) JP6185932B2 (enExample)
CN (1) CN104159606A (enExample)
AU (1) AU2013207962B2 (enExample)
BR (1) BR112014017242A8 (enExample)
CA (1) CA2861021A1 (enExample)
HK (1) HK1203837A1 (enExample)
WO (1) WO2013106525A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
BR112016006344A2 (pt) 2013-09-12 2018-01-09 Leidos Inc vacina contra a malária, composição e métodos
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
US10821167B2 (en) 2016-02-02 2020-11-03 Unm Rainforest Innovations VLP-based vaccines for targeting Staphylococcus aureus secreted virulence factors
AU2017263138B2 (en) 2016-05-13 2022-08-25 Flash Therapeutics Viral particle for RNA transfer, especially into cells involved in immune response
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
AU2018342997C1 (en) 2017-09-29 2024-07-04 Deutsches Krebsforschungszentrum Cutaneous papilloma virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2005281743A1 (en) * 2004-08-04 2006-03-16 Cytos Biotechnology Ag Carrier conjugates of GnRH-peptides
WO2011100234A2 (en) * 2010-02-09 2011-08-18 Stc.Unm Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

Similar Documents

Publication Publication Date Title
JP2015504897A5 (enExample)
Jain et al. Formulation and stabilization of recombinant protein based virus-like particle vaccines
JP2016155867A5 (enExample)
JP2012010713A5 (enExample)
JP2014530010A5 (enExample)
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
CN106659777A8 (zh) 免疫原性组合产品
SG131116A1 (en) Functional influenza virus-like particles (vlps)
JP2014502156A5 (enExample)
WO2020163719A3 (en) Nanoparticle-based influenza virus vaccines and uses thereof
MX376568B (es) Vacunas mejoradas para el virus del papiloma humano y métodos para utilizarlas.
WO2011085231A3 (en) Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
SG10201903538YA (en) Modified virus-like particles of cmv
JP2014507144A5 (ja) 慢性b型肝炎感染症のための酵母系免疫療法組成物
NZ595710A (en) Recombinant virus-like particles encoded by multi-gene vector
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
JP2015524422A5 (enExample)
HK1208355A1 (en) Universal influenza vaccine based on heterologous multiple m2e proteins
JP2006512413A5 (enExample)
JOP20220187A1 (ar) لقاح فيروس الورم الحليمي البشري (hpv)
JP2013541528A5 (enExample)
MY197457A (en) Chimeric papillomavirus l1 protein
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same
Sharma et al. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer